Alterity Therapeutics Limited Appendix 4D Half-year ended 31 December 2023 Name of entity: Alterity Therapeutics Limited ABN: 37 080 699 065 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for

Alterity Therapeutics Limited

Half-year ended 31 December 2023

Results for announcement to the market

Net tangible assets per security

Explanation of results

Alterity Therapeutics Limited

recorded income of $118,400 for the half-year ended 31 December 2023 (2022: $11,379) which is interest received on the Group's

bank accounts. Alterity Therapeutics Limited has incurred a loss of $6,507,183 for the half-year ended 31 December 2023 (2022:

An explanation of the key financial

elements contributing to the revenue and result above can be found in the review of operations included within the directors' report.

No dividends have been paid or declared

by the Group for the current financial period. No dividends were paid for the previous financial period.

Changes in controlled entities

There have been no changes in controlled

entities during the period ended 31 December 2023.

Other information required by Listing

The interim financial statements have

been reviewed by the Group's independent auditor which includes a paragraph regarding a material uncertainty in relation to going concern.

Therapeutics Limited

financial report for the

ended 31 December 2023

Therapeutics Limited

Alterity Therapeutics Limited

present their report on the Consolidated Entity (referred to hereafter as the group) consisting of Alterity Therapeutics Limited and

the entities it controlled at the end of, or during, the half-year ended 31 December 2023.

The following persons held office as

directors of Alterity Therapeutics Limited during the whole of the half-year and up to the date of this report:

Mr. Geoffrey Kempler

Review of operations

of FY24, Alterity delivered material progress on all aspects of the business. Both of the Company's Phase 2 clinical trials advanced

on schedule with the ATH434-201 randomized, double-blind trial completing enrollment. Numerous data presentations were given at prominent

medical meetings during the period, highlighted by new, preclinical data on the potential efficacy of ATH434 in Parkinson's disease.

In addition, the Company successfully completed a financing round with new investors and current shareholders to continue this momentum

into the second half of FY24.

All these advancements demonstrate Alterity's

ability to deliver on its clinical pipeline and corporate objectives as it strives to develop the first disease modifying treatment for

a rare neurodegenerative disease.

30 June 2023 Annual Report contains detailed background information relating to its operations including its research and development

projects and collaboration partners and should be read in conjunction with this report.

Development Pipeline

Lead Compound - ATH434

Discovered internally,

Alterity's lead compound ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.

ATH434 acts by redistributing excess iron in the brain, reducing the toxic accumulation of the protein -synuclein, and rescuing

neuronal function. As an iron chaperone, ATH434 has the potential to address the underlying pathology of the disease and preserve function

in individuals with Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA).

Based on accumulated

pre-clinical data and an understanding of how MSA develops and progresses, the Company believes ATH434 has excellent potential to treat

MSA as well as Parkinson's disease. ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and

achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials

granted Orphan Drug Designation (ODD) for the treatment of MSA by the U.S. FDA and the European Commission. ODD comes with many benefits

including 7-10 years of market exclusivity, tax credits and fee reductions, as well as protocol assistance from each agency.

Alterity Therapeutics Limited

Review of operations

- 31 December 2023 (continued)

for ATH434 as a Treatment for Neurodegenerative Diseases

Year, on 16 November 2023, Alterity announced that promising new data related to ATH434 was presented at the Society for Neuroscience.

The poster entitled, "Potent Antioxidant and Mitochondrial- protectant Effects of ATH434, a Novel Inhibitor of -Synuclein

Aggregation with Moderate Iron- binding Affinity," demonstrated new data indicating that ATH434 can preserve mitochondrial function

after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties. These features were not observed

with another iron binding agent approved for treating iron overload that was also investigated. The demonstrated mitochondrial protection

may reveal additional mechanisms that augment the ability of ATH434 to slow disease progression and underscores the potential of ATH434

as a treatment for neurodegenerative diseases.

Progress in Ongoing Clinical

and Research Pipeline in Multiple System Atrophy

Alterity made substantial

progress in the first half of FY24 advancing its clinical and research programs in the rare, orphan indication of multiple system atrophy

MSA is a rare neurodegenerative

disease, related to Parkinson's, that progresses rapidly and causes profound disability. While some of the symptoms of MSA can

be treated with available medications, currently there are no drugs that can slow disease progression and there is no cure. MSA is a

Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects

involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes

to falls, all of which drastically impair quality of life.

hallmark of MSA is accumulation of the protein alpha-synuclein and neuron loss in multiple brain regions within the central nervous system.

The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord.

clinical trials are evaluating the effect of the ATH434 treatment on neuroimaging and protein biomarkers to demonstrate target engagement

and clinical endpoints that assess the key symptoms of MSA, in addition to assessing safety and pharmacokinetics. The selected biomarkers,

such as brain iron and aggregating -synuclein, are important contributors to MSA pathology and are therefore appropriate targets

to demonstrate drug activity. Wearable sensors are being used in the ATH434-201 study to evaluate motor activities important to individuals

with MSA in an outpatient setting.

Randomized, Double-Blind Phase 2 Clinical Trial in Early-State MSA

Alterity announced that enrollment was successfully completed in the ATH434-201 Phase 2 clinical trial. This is the Company's primary

clinical trial and is a randomized, double-blind, placebo-controlled study that enrolled participants with early-stage MSA across the

U.S., Europe, Australia and New Zealand. The ATH434-201 study is treating participants for 12 months and, therefore, the study will complete

in November 2024. Once complete, the data from the trial will be analyzed and the Company expects to report topline results by January

important milestone was reached in the trial when the independent Data Monitoring Committee (DMC) for the trial recommended the Phase

2 study continue as planned. The DMC conducted a prespecified review of unblinded clinical data from an initial cohort of study participants.

The DMC expressed no concerns about safety and recommended that the study continue without modification. The plan for the DMC to review

initial safety data was cleared with the U.S. Food and Drug Administration.

On 6 February 2024, the DMC for the trial conducted its second prespecified review of unblinded clinical data from study participants.

The DMC again expressed no concerns about safety and recommended that the study continue without modification.

Alterity Therapeutics Limited

Review of operations - 31 December 2023 (continued)

Open-label, Biomarker Phase 2 Clinical Trial in More Advanced MSA

trial continues to evaluate participants with more advanced MSA when compared to the cohort from the 201 trial. While the 202 trial is